Kadmon Holdings Inc (NYSE:KDMN) gapped up prior to trading on Tuesday after an insider bought additional shares in the company. The stock had previously closed at $4.23, but opened at $4.13. Kadmon shares last traded at $4.17, with a volume of 180,446 shares.
Specifically, major shareholder Perceptive Advisors Llc bought 1,470,588 shares of Kadmon stock in a transaction on Monday, November 18th. The shares were bought at an average price of $3.40 per share, for a total transaction of $4,999,999.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.85% of the stock is owned by company insiders.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Kadmon from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. ValuEngine cut shares of Kadmon from a “hold” rating to a “sell” rating in a research report on Wednesday, November 13th. Finally, Cantor Fitzgerald lifted their target price on shares of Kadmon from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $9.35.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Capital Investment Advisors LLC increased its position in shares of Kadmon by 134.5% during the second quarter. Capital Investment Advisors LLC now owns 28,815 shares of the company’s stock worth $59,000 after acquiring an additional 16,525 shares during the period. GSA Capital Partners LLP grew its stake in Kadmon by 143.5% during the 2nd quarter. GSA Capital Partners LLP now owns 54,760 shares of the company’s stock worth $113,000 after purchasing an additional 32,268 shares in the last quarter. Vanguard Group Inc. grew its stake in Kadmon by 5.9% during the 2nd quarter. Vanguard Group Inc. now owns 5,713,561 shares of the company’s stock worth $11,770,000 after purchasing an additional 320,710 shares in the last quarter. BlackRock Inc. raised its position in Kadmon by 23.5% in the 2nd quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock valued at $17,363,000 after purchasing an additional 1,605,568 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new position in shares of Kadmon in the 2nd quarter valued at about $319,000. 76.80% of the stock is currently owned by hedge funds and other institutional investors.
Kadmon Company Profile (NYSE:KDMN)
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Article: Hang Seng Index (HSI)
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.